Pengakuan

This work was supported by grants from that National Institute of Diabetes and Digestive
and Kidney Diseases (DK-065074-01 to Youfei Guan [YG], DK-37097 to Matthew Breyer)
and the Ameri-can Heart Association (AHA160200B to YG).
I thank Dr. Matthew Breyer for helpful discussion and critical reading of this manuscript. I
also thank many colleagues and collab-orators for contributions to our research described in
this review.
Referensi
Guan Y, Breyer MD: Peroxisome proliferator-activated receptors (PPARs): Novel
therapeutic targets in renal disease. Kidney Int
14 -30, 2001
Fajas L, Debril MB, Auwerx J: Peroxisome proliferator-activated receptor-gamma: From
adipogenesis to carcinogenesis. J Mol Endocrinol 27: 1-9, 2001
Desvergene B, Wahli W: Peroxisome proliferator-activated re-ceptor: Nuclear control of
metabolism. Endocr Rev 20: 649 - 688, 1999
Willson TM, Lambert MH, Kliewer SA: Peroxisome prolifera-tor-activated receptor gamma
and metabolic disease. Annu Rev Biochem 70: 341-367, 2001
Scott CL: Diagnosis, prevention, and intervention for the meta-bolic syndrome. Am J
Cardiol 92: 35i- 42i, 2003
Ginsberg HN: Treatment for patients with the metabolic syn-drome. Am J Cardiol 91: 29E-
39E, 2003
Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S: The meta-bolic syndrome: Peroxisome
proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol
Metab
2412-2421, 2003
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism
of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088 -2093, 1998
Jones AB: Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and
beyond. Med Res Rev 21: 540 -552, 2001
Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA,
Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller
DE, Auwerx J: Activation of PPAR alters lipid metabolism in db/db mice. FEBS Lett 473:
333-336, 2000
2810 Journal of the American Society of Nephrology
Hsueh WA, Bruemmer D: Peroxisome proliferator-activated re-ceptor gamma: Implications
for cardiovascular disease. Hyper-tension 43: 297-305, 2004
Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by
peroxisome proliferators. Na-ture 347: 645- 650, 1990
Moras D, Gronemeyer H: The nuclear receptor ligand-binding domain: Structure and
function. Curr Opin Cell Biol 3: 384 -391, 1998
Fajas L, Auboeuf D, Rasp E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M,
Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J: The
organization, promoter analysis, and expression of the human PPAR gene. J Biol
Chem 272: 18779 -18789, 1997
Fajas L, Fruchart JC, Auwerx J: PPAR 3 mRNA: A distinct PPAR mRNA subtype transcribed
from an independent pro-moter. FEBS Lett 438: 55- 60, 1998
Ricote M, Valledor AF, Glass CK: Decoding transcriptional programs regulated by PPARs
and LXRs in the macrophage: Effects on lipid homeostasis, inflammation, and
atherosclerosis.
Arterioscler Thromb Vasc Biol 24: 230 -239, 2004
Guan Y, Breyer MD: Targeting peroxisome proliferator-acti-vated receptors (PPARs) in
kidney and urologic disease. Minerva Urol Nefrol 54: 65-79, 2002
Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli
W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene
expres-sion through direct interactions with peroxisome proliferator-activated receptors
and . Proc Natl Acad Sci USA 94: 4318 - 4323, 1997
Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, Capdevila JH: The CYP4A
isoforms hydroxylate epoxyei-cosatrienoic acids to form high affinity peroxisome
proliferator-activated receptor ligands. J Biol Chem 277: 35105-35112, 2002
Brown PJ, Smith-Oliver TA, Charifson PS, Tomkinson NC, Fivush AM, Sternbach DD, Wade
LE, Orband-Miller L, Parks DJ, Blanchard SG, Kliewer SA, Lehmann JM, Willson TM:
Identification of peroxisome proliferator-activated receptor li-gands from a biased
chemical library. Chem Biol 4: 909 -918, 1997
Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer
SM, Lippman SM: The 15-lipoxy-genase-1 product 13-S-hydroxyoctadecadienoic acid
down-reg-ulates PPAR-delta to induce apoptosis in colorectal cancer cells.
 Proc Natl Acad Sci USA 100: 9968 -9973, 2003
Forman B, Tontonoz P, Chen J, Brun R, Spiegelman B, Evans R: 15-Deoxy- 12,14-
prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-gamma. Cell 83:
803- 812, 1995
Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RA: Oxidized LDL regulates macrophage
gene expression through ligand ac-tivation of PPAR . Cell 93: 229 -240, 1998
Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPAR promotes
monocyte/macrophage differentiation and up-take of oxidized LDL. Cell 93: 241-252,
1998
Qi C, Zhu Y, Reddy JK: Peroxisome proliferator-activated re-ceptors, coactivators, and
downstream targets. Cell Biochem Biophys 32: 187-204, 2000
Guan Y, Zhang Y, Davis L, Breyer MD: Expression of peroxi-some proliferator-activated
receptors in urinary tract of rabbits and humans. Am J Physiol 273: F1013-F1022, 1997
Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M,
Vidal H: Tissue distribution and

J Am Soc Nephrol 15: 2801-2815, 2004

quantification of the expression of mRNAs of peroxisome pro-liferator-activated receptors
and liver X receptor- in humans. No alteration in adipose tissue of obese and NIDDM
patients. Diabetes 46: 1319 -1327, 1997
Mukherjee R, Noonan LJD, McDonnell DP: Human and rat peroxisome proliferator activated
receptors (PPARs) demon-strate similar tissue distribution but different responsiveness to
PPAR activators. J Steroid Biochem Mol Biol 51: 157-166, 1994
Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z: PPAR agonists
protect mesangial cells from inter-leukin 1 -induced intracellular lipid accumulation by
activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14: 593- 600, 2003
Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD: Peroxisome proliferator-
activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol
Renal Physiol 281: F1036 -F1046, 2001
Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:
1595-1607, 1988
Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its
complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of
a WHO consultation. Diabet Med 15: 539 -553, 1998
Kereiakes DJ, Willerson JT: Metabolic syndrome epidemic. Cir-culation 108: 1552-1553,
2003
Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults:
Findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356
-359, 2002
Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L:
Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes
Care 24: 683- 689, 2001
Henry RR: Insulin resistance: From predisposing factor to ther-apeutic target in type 2
diabetes. Clin Ther 25[Suppl B]: B47- B63, 2003
Stolar MW, Chilton RJ: Type 2 diabetes, cardiovascular risk, and the link to insulin
resistance. Clin Ther 25[Suppl B]: B4 -B31, 2003
Lebovitz HE: The relationship of obesity to the metabolic syn-drome. Int J Clin Pract
Suppl (134): 18 -27, 2003
Williams G: Obesity and type 2 diabetes: A conflict of interests?
Int J Obes Relat Metab Disord 23[Suppl 7]: S2-S4, 1999
Stumvoll M, Haring H: Insulin resistance and insulin sensitizers. Horm Res 55[Suppl 2]: 3-13,
2001
Siegel RD, Cupples A, Schaefer EJ, Wilson PW: Lipoproteins, apolipoproteins, and low-
density lipoprotein size among diabet-ics in the Framingham offspring
study. Metabolism 45: 1267- 1272, 1996
Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol
lowering with simvastatin improves prognosis of diabetic patients with coronary heart
disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes
Care 20: 614 - 620, 1997
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E,
Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of
coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
Veterans Affairs High-Density Lipoprotein Choles-terol Intervention Trial Study Group. N
Engl J Med 341: 410 - 418, 1999

J Am Soc Nephrol 15: 2801-2815, 2004

Reddy JK: Nonalcoholic steatosis and steatohepatitis. AKU AKU AKU. Perox-isomal beta-
oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 281:
G1333-G1339, 2001
Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-
activated receptor alpha (PPAR ) in the cellular fasting response: The PPAR -null
mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96: 7473-
7478, 1999
Neve BP, Fruchart JC, Staels B: Role of the peroxisome prolif-erator-activated receptors
(PPAR) in atherosclerosis. Biochem Pharmacol 60: 1245-1250, 2000
Fruchart JC: Peroxisome proliferator-activated receptor-alpha activation and high-density
lipoprotein metabolism. Am J Car-diol 88: 24N-29N, 2001
Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: Expression of putative fatty acid
transporter gene are regulated by peroxisome proliferator-activated receptor and activators
in a tissue- and inducer-specific manner. J Biol Chem 273: 16710 -16714, 1998
Seedorf U, Assmann G: The role of PPAR alpha in obesity. Nutr Metab Cardiovasc Dis 11:
189 -194, 2001
Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T: Peroxisome proliferator-activated
receptor alpha-isoform defi-ciency leads to progressive dyslipidemia with sexually
dimorphic obesity and steatosis. J Biol Chem 273: 29577-29585, 1998
Vazquez M, Merlos M, Adzet T, Laguna JC: Decreased suscep-tibility to copper-induced
oxidation of rat-lipoproteins after fi-brate treatment: Influence of fatty acid composition. Br
J Phar-macol 117: 1155-1162, 1996
Kim BH, Won YS, Kim EY, Yoon M, Nam KT, Oh GT, Kim DY: Phenotype of peroxisome
proliferator-activated receptor-alpha(PPAR )deficient mice on mixed background fed high
fat diet. J Vet Sci 4: 239 -244, 2003
Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, Larsen TS:
Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744,
a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 283: H949 -H957, 2002
Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU: Peroxisome
proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats:
Comparison with PPAR-gamma activation. Diabetes 52: 2331-2337, 2003
Park CW, Zhang Y, Fan XF, Davis L, Capdevila JH, Guan Y, Breyer MD: A PPAR alpha
agonist improves diabetic nephrop-athy in db/db mice. J Am Soc Nephrol 14: 393A, 2003
 Panz VR, Wing JR, Raal FJ, Kedda MA, Joffe BI: Improved glucose tolerance after effective
lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: A
putative role for Randle's cycle in its pathogenesis? Clin Endo-crinol (Oxf) 46: 365-368,
1997
Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPAR activators inhibit cytokine-
induced vascular cell adhesion mole-cule-1 expression in human endothelial
cells. Circulation 99: 3125-3131, 1999
Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti
G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth muscle
cells is inhibited by PPAR but not PPAR activators. Nature 393: 790 -793, 1998
Kintscher U, Lyon C, Wakino S, Bruemmer D, Feng X, Goetze S, Graf K, Moustakas A,
Staels B, Fleck E, Hsueh WA, Law RE, Diep QN, Touyz RM, Schiffrin EL: PPAR inhibits
TGF- -

PPAR and Renal Complications of the

Metabolic Syndrome 2811

induced 5 integrin transcription in vascular smooth muscle cells by interacting with

Smad4. Circ Res 91: e35- e44, 2002
Diep QN, Touyz RM, Schiffrin EL: Docosahexaenoic acid, a peroxisome proliferator-activated
receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of
p38 mitogen-activated protein kinase. Hypertension 36: 851- 855, 2000
Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL: PPAR
activator effects on Ang II-induced vascular oxidative stress and
inflammation. Hypertension 40: 866 - 871, 2002
Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, Kovacs WJ, Magnuson MA, Keeney
DS, Breyer MD, Falck JR, Water-man MR, Capdevila JH: Alterations in the regulation of
andro-gen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci
USA 98: 5211-5216, 2001
Capdevila JH, Falck JR, Harris RC: Cytochrome P450 and arachidonic acid bioactivation.
Molecular and functional proper-ties of the arachidonate monooxygenase. J Lipid Res 41:
163- 181, 2000
Johnson EF, Palmer CNA, Griffin KJ, Hsu MH: Role of the peroxisome proliferator-activated
receptor in cytochrome P450 4A gene regulation. FASEB J 10: 1241-1248, 1996
Roman RJ, Ma YH, Frohlich B, Markham B: Clofibrate prevents the development of
hypertension in Dahl salt-sensitive rats. Hy-pertension 21: 985-988, 1993
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton
CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B: Reduction of atherosclerosis by
the peroxisome proliferator-activated receptor alpha agonist fe-nofibrate in mice. J Biol
Chem 277: 48051- 48057, 2002
Rubins HB, Robins SJ: Conclusions from the VA-HIT study. Am J Cardiol 86: 543-544, 2000
Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Ander-son JW, Collins D: Insulin
resistance and cardiovascular events with low HDL cholesterol: The Veterans Affairs HDL
Interven-tion Trial (VA-HIT). Diabetes Care 26: 1513-1517, 2003
Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K: Peroxisome
proliferator-activated receptor delta (PPAR )-mediated regulation of preadipocyte
proliferation and gene expression is dependent on cAMP signaling. J Biol Chem 276: 3175-
3182, 2001
Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD,
Gonzalez FJ: Growth, adipose, brain, and skin alterations resulting from targeted disruption
of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 20: 5119
-5128, 2000
Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM: Effects of
peroxisome proliferator-acti-vated receptor delta on placentation, adiposity, and colorectal
cancer. Proc Natl Acad Sci USA 99: 303-308, 2002
Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-
activated receptor delta activates fat me-tabolism to prevent obesity. Cell 113: 159 -170,
2003
Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar
DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC,
Willson TM: A selective peroxisome proliferator-activated receptor delta agonist promotes
reverse cholesterol transport. Proc Natl Acad Sci USA 98: 5306 -5311, 2001
Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K,
Ioka RX, Tachibana K, Watanabe
 2812 Journal of the American Society of Nephrology J Am Soc Nephrol 15: 2801-2815,
2004
Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J,
Yanagisawa M, Kodama T, Sakai J: Acti-vation of peroxisome proliferator-activated
receptor delta in-duces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic
syndrome. Proc Natl Acad Sci USA 100: 15924 - 15929, 2003
Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE: The peroxisome proliferator-
activated receptor beta/delta ago-nist, GW501516, regulates the expression of genes
involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol
Endocrinol 17: 2477-2493, 2003
Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA:
Peroxisome proliferator-acti-vated receptor delta controls muscle development and
oxidative capability. FASEB J 17: 2299 -2301, 2003
Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, Evans RM: PPAR
is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100:
1268 - 1273, 2003
Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK:
Transcriptional repression of atherogenic in-flammation: modulation by PPAR
. Science 302: 453- 457, 2003
Lowell BB: PPAR : An essential regulator of adipogenesis and modulator of fat cell
function. Cell 99: 239 -242, 1999
Brun RP, Tontonoz P, Forman BM, Ellis R, Chen J, Evans RM, Spiegelman BM: Differential
activation of adipogenesis by mul-tiple PPAR isoforms. Genes Dev 10: 974 -984, 1996
Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne
PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK: A dominant-
negative peroxisome proliferator-activated receptor gamma (PPAR ) mu-tant is a
constitutive repressor and inhibits PPAR -mediated adipogenesis. J Biol Chem 275: 5754 -
5759, 2000
Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM,
Mortensen RM: PPAR gamma is required for the differentiation of adipose tissue in vivo
and in vitro. Mol Cell 4: 611- 617, 1999
Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a
mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339: 953-959,
1998
Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto
W, Auwerx J: A Pro12Ala substitution in PPAR 2 associated with decreased receptor ac-
tivity, lower body mass index and improved insulin sensitivity. Nat Genet 20: 284 -287,
1998
Zimmet P: Addressing the insulin resistance syndrome: A role for the
thiazolidinediones. Trends Cardiovasc Med 12: 354 -362, 2002
Moller DE: New drug targets for type 2 diabetes and the meta-bolic syndrome. Nature 414:
821- 827, 2001
Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL,
Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative
mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and
hypertension. Nature 402: 880 - 883, 1999
Kumar S, Prange A, Schulze J, Lettis S, Barnett AH: Troglita-zone, an insulin action enhancer,
improves glycaemic control and insulin sensitivity in elderly type 2 diabetic
patients. Diabet Med 15: 772-779, 1998
Mukherjee R, Davies PJ, Crombier DL, Bischoff ED, Cesario RM, Jow L, Hamanns LG,
Boehm MF, Mondon CE, Nadzan
AM, Paterniti JR Jr, Heyman RA: Sensitization of diabetic and obese mice to insulin by
retinoid X receptor agonists. Nature
386: 407- 414, 1997
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of
9- cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer
formation of their re-ceptors. Nature 358: 771-774, 1992
Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R,
Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa
G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S,
Kadowaki T, et al. : PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy
and insulin resistance. Mol Cell 4: 597- 609, 1999
Miles PDG, Barak Y, He W, Evans RM, Olefsky JM: Improved insulin-sensitivity in mice
heterozygous for PPAR deficiency. J Clin Invest 105: 287-292, 2000
Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N,
Terauchi Y, Tsuchida A, Tsuboyama-Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S,
Fukayama M, Akanuma Y, Ezaki O, Itai A, Nagai R, Kimura S, Tobe K, Kagechika H,
 Shudo K, Kadowaki T: Inhibition of RXR and PPAR ameliorates diet-induced obesity and
type 2 diabetes. J Clin Invest 108: 1001-1013, 2001
Shuldiner AR, Yang R, Gong DW: Resistin, obesity and insulin resistance--The emerging
role of the adipocyte as an endocrine organ. N Engl J Med 345: 1345-1346, 2001
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS,
Lazar MA: The hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001
Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S:
Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated
receptor-gamma action in humans. Diabetes 50: 2199 -2202, 2001
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami
K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML,
Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M,
Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance
associated with both li-poatrophy and obesity. Nat Med 7: 941-946, 2001
Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai
TY, Chuang LM: Synthetic peroxi-some proliferator-activated receptor-gamma agonist,
rosiglita-zone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes
Care 25: 376 -380, 2002
Fasshauer M, Paschke R: Regulation of adipocytokines and insulin
resistance. Diabetologia 46: 1594 -1603, 2003
Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH,
O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ,
Charron MJ, Scherer PE, Moller DE: Induction of adipocyte complement-related protein
of 30 kilodaltons by PPAR agonists: A potential mechanism of insulin
sensitization. Endocrinology143: 998 - 1007, 2002
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic
syndrome. Arterioscler Thromb Vasc Biol 24: 29 -33, 2004
Lee CH, Olson P, Evans RM: Minireview: Lipid metabolism, metabolic diseases, and
peroxisome proliferator-activated recep-tors. Endocrinology 144: 2201-2207, 2003

J Am Soc Nephrol 15: 2801-2815, 2004 PPAR and Renal Complications of the Metabolic
Syndrome 2813
Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby
AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F,
Chat-terjee VK, O'Rahilly S: Human metabolic syndrome resulting from dominant-
negative mutations in the nuclear receptor per-oxisome proliferator-activated receptor-
gamma. Diabetes 52: 910 -917, 2003
Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW: Troglitazone
monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A
randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab
3169 -3176, 1998
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone
hydrochloride monotherapy im-proves glycemic control in the treatment of patients with
type 2 diabetes: A 6-month randomized placebo-controlled dose-re-sponse study. The
Pioglitazone 001 Study Group. Diabetes Care
1605-1611, 2000
Komers R, Vrana A: Thiazolidinediones--Tools for the research of metabolic syndrome
X. Physiol Res 47: 215-225, 1998
Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD: Effects
of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities
in type 2 diabetes mellitus. Am J Cardiol 90: 947-952, 2002
Tack CJ, Smits P, Demacker PN, Stalenhoef AF: Troglitazone decreases the proportion of
small, dense LDL and increases the resistance of LDL to oxidation in obese
subjects. Diabetes Care
796 -799, 1998
King AB, Armstrong DU: Lipid response to pioglitazone in diabetic patients: Clinical
observations from a retrospective chart review. Diabetes Technol Ther 4: 145-151, 2002
Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and
metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J
Med338: 867- 872, 1998
Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: En-hancement of insulin sensitivity
by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertension 8: 316
- 320, 1995
Saku K, Zhang B, Ohta T, Arakawa K: Troglitazone lowers blood pressure and enhances
insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am J Hypertens 10: 1027-
1033, 1997
Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R,
Aikawa E, Demura H: Antihyper-tensive and vasculo- and renoprotective effects of
pioglitazone in genetically obese diabetic rats. Am J Physiol 272: E989 -E996, 1997
Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI: Rosiglitazone reduces
urinary albumin excretion in type II diabetes. J Hum Hypertens 17: 7-12, 2003
Uchida A, Nakata T, Hatta T, Kiyama M, Kawa T, Morimoto S, Miki S, Moriguchi J,
Nakamura K, Fujita H, Itoh H, Sasaki S, Takeda K, Nakagawa M: Reduction of insulin
resistance atten-uates the development of hypertension in sucrose-fed SHR. Life Sci 61:
455- 464, 1997
Walker AB, Chattington PD, Buckingham RE, Williams G: The thiazolidinedione
rosiglitazone (BRL-49653) lowers blood pres-sure and protects against impairment of
endothelial function in Zucker fatty rats. Diabetes 48: 1448 -1453, 1999
Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, Tago K, Irie K, Muraki
T, Demura H, Zardi L:
Vasculo-protective effects of insulin sensitizing agent pioglita-zone in neointimal
thickening and hypertensive vascular hyper-trophy. Atherosclerosis 145: 333-340, 1999
Grinsell JW, Lardinois CK, Swislocki A, Gonzalez R, Sare JS, Michaels JR, Starich GH:
Pioglitazone attenuates basal and post-prandial insulin concentrations and blood pressure
in the spon-taneously hypertensive rat. Am J Hypertens 13: 370 -375, 2000
Sung BH, Izzo JL Jr, Dandona P, Wilson MF: Vasodilatory effects of troglitazone improve
blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 34:
83- 88, 1999
Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, Sugimoto N, Liang YQ, Sudoh
N, Toba K, Ouchi Y: Expression of peroxisome proliferator-activated receptor (PPAR ) in
rat aortic smooth muscle cells. Biochem Biophys Res Commun 247: 353-356, 1998
Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh
WA: Expression and function of PPAR in rat and human vascular smooth muscle
cells. Circulation 101: 1311-1318, 2000
Marx N, Schnbeck U, Lazar MA, Libby P, Plutzky J: Peroxi-somal proliferator-activated
receptor gamma activators inhibit gene expression and migration in human vascular smooth
muscle cells. Circ Res 83: 1097-1103, 1998
Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J: PPAR activation in human endothelial
cells increases plasminogen ac-tivator inhibitor type-1 expression: PPAR as a potential
medi-ator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546 -551, 1999
Satoh H, Tsukamoto Y, Hashimoto N, Togo M, Hara M, Maekawa H, Isoo N, Kimura S,
Watanabe T: Thiazolidinediones suppress endothelial-1 secretion from bovine vascular
endothe-lial cells: A new possible role of PPAR on vascular endothelial function. Biochem
Biophys Res Commun 254: 757-763, 1999
Zhang HY, Reddy SR, Kotchen TA: Antihypertensive effect of pioglitazone is not invariably
associated with increased insulin sensitivity. Hypertension 24: 106 -110, 1994
Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD: PPAR(gamma) agonist rosiglitazone
improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hy-
pertension 43: 661- 666, 2004
Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL:
Structure, endothelial func-tion, cell growth, and inflammation in blood vessels of angio-
tensin II-infused rats: Role of peroxisome proliferator-activated receptor-
gamma. Circulation 105: 2296 -2302, 2002
Fujiwara T, Ohsawa T, Takahashi S, Ikeda K, Okuno A, Ush-iyama S, Matsuda K, Horikoshi
H: Troglitazone, a new antidia-betic agent possessing radical scavenging ability, improved
de-creased skin blood flow in diabetic rats. Life Sci 63: 2039 -2047, 1998
Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh
WA: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin
Invest 96: 354 -360, 1995
Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW:
Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46: 433- 439,
1997
Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G: Differential
vasoactive effects of the insulin sensi-tizers rosiglitazone (BRL 49653) and troglitazone on
human small arteries in vitro. Diabetes 47: 810 - 814, 1998

2814 Journal of the American Society of Nephrology J Am Soc Nephrol 15: 2801-2815,
2004
Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL: Pioglitazone prevents hypertension and
reduces oxidative stress in diet-in-duced obesity. Hypertension 43: 48 -56, 2004
Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A:
Peroxisome proliferator-activated re-ceptor gamma activators downregulate angiotensin II
type 1 receptor in vascular smooth muscle cells. Circulation 102: 1834 -1839, 2000
Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, Thompson P, Shou Y,
O'Shaughnessy K, Ronco P, Brown J: PPAR activation enhances cell surface ENaC via up-
regula-tion of SGK1 in human collecting duct cells. FASEB J 17: 1966 -1968, 2003
Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC III, Schnermann JB, Briggs JP:
Expression of peroxisomal prolifera-tor-activated receptors and retinoid X receptors in the
kidney. Am J Physiol 277: F966 -F973, 1999
Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-
activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-
deficient mice. J Clin Invest 106: 523-531, 2000
Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of
troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol
Metab 83: 1818 - 1820, 1998
Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA,
Law RE: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and
nondi-abetic low density lipoprotein receptor-deficient mice. Arterio-scler Thromb Vasc
Biol 21: 365-371, 2001
Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards
PA, Curtiss LK, Evans RM, Tontonoz P: A PPAR gamma-LXR-ABCA1 pathway in
macro-phages is involved in cholesterol efflux and atherogenesis. Mol Cell 7: 161-171,
2001
Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye
M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B: PPAR-alpha and PPAR-
gamma activators induce cholesterol removal from human macrophage foam cells through
stimulation of the ABCA1 pathway. Nat Med 7: 53-58, 2001
Jiang C, Ting AT, Seed B: PPAR agonists inhibit production of monocyte inflammatory
cytokines. Nature 391: 82- 86, 1998
Poynter ME, Daynes RA: Peroxisome proliferator-activated re-ceptor alpha activation
modulates cellular redox status, represses nuclear factor- B signaling, and reduces
inflammatory cytokine production in aging. J Biol Chem 273: 32833-32841, 1998
Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J,
Najib J, Staels B: Activation of proliferator-activator receptors and induces apoptosis of
human monocyte-derived macrophages. J Biol Chem 273: 25573-25580, 1998
Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D: Troglitazone inhibits
vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98: 1897-1905,
1996
Daynes RA, Jones DC: Emerging roles of PPARs in inflamma-tion and immunity. Nat Rev
Immunol 2: 748 -759, 2002
Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-acti-vated receptors in
inflammation control. J Endocrinol 169: 453- 459, 2001
Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T: A
novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-
alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activa-tion on abnormal
lipid metabolism in liver of Zucker fatty rats. Diabetes 47: 1841-1847, 1998
Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ: The ontogeny of peroxisome-
proliferator-activated receptor gene expression in the mouse and rat. Proc R Soc Lond B
Biol Sci 247: 83- 87, 1992
Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD: Etomoxir-induced PPAR -
modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 278:
F667-F675, 2000
Portilla D: Energy metabolism and cytotoxicity. Semin Nephrol 23: 432- 438, 2003
Ouali F, Djouadi F, Merlet-Bnichou C, Bastin J: Dietary lipids regulate -oxidation enzyme
gene expression in the developing rat kidney. Am J Physiol 275: F777-F784, 1998
Sugden MC, Bulmer K, Gibbons GF, Holness MJ: Role of peroxisome proliferator-activated
receptor-alpha in the mecha-nism underlying changes in renal pyruvate dehydrogenase
kinase isoform 4 protein expression in starvation and after refeeding.
Arch Biochem Biophys 395: 246 -252, 2001
Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP: A
critical role for PPAR -mediated lipotoxicity in the pathogenesis of diabetic
cardiomyopathy: Modulation by dietary fat content. Proc Natl Acad Sci USA 100: 1226 -
1231, 2003
Mishra R, Emancipator SN, Miller C, Kern T, Simonson MS: Adipose differentiation related
protein and regulates of lipid homeostasis identified by gene expression profiling in murine
db/db diabetic kidney. Am J Physiol Renal Physiol 286: F913- F921, 2004
Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease:
A meta-analysis. Kidney Int 59: 260 -269, 2001
Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J: Can
reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with
non-insulin-dependent diabetes mellitus? Eur J Clin Invest 27: 997- 1002, 1997
Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S,
Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D: Peroxisome proliferator-
activated re-ceptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses
the lipotoxic state and improves glucose ho-meostasis. Diabetes 52: 1770 -1778, 2003
Scholz-Pedretti K, Gans A, Beck KF, Pfeilschifter J, Kaszkin M: Potentiation of TNF-alpha-
stimulated group IIA phospholipase A(2) expression by peroxisome proliferator-activated
receptor alpha activators in rat mesangial cells. J Am Soc Nephrol 13: 611- 620, 2002
Wilmer WA, Dixon CL, Hebert C, Lu L, Rovin BH: PPAR-alpha ligands inhibit H2O2-
mediated activation of transforming growth factor-beta1 in human mesangial
cells. Antioxid RedoxSignal 4: 877- 884, 2002
Kamijo Y, Hora K, Tanaka N, Usuda N, Kiyosawa K, Nakajima T, Gonzalez FJ, Aoyama T:
Identification of functions of perox-isome proliferator-activated receptor alpha in proximal
tubules. J Am Soc Nephrol 13: 1691-1702, 2002

J Am Soc Nephrol 15: 2801-2815, 2004 PPAR and Renal Complications of the Metabolic
Syndrome 2815
Hao CM, Redha R, Morrow J, Breyer MD: Peroxisome prolif-erator-activated receptor delta
activation promotes cell survival following hypertonic stress. J Biol Chem 277: 21341-
21345, 2002
Hao CM, Redha R, Morrow J, Guan YF, Breyer MD: Hypertonic stress induces COX2
dependent prostacyclin synthesis in renal medullary interstitial cell (RMICs) and down-
stream activation of PPAR dependent survival mechanism. J Am Soc Nephrol 12: 49A,
2001
Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 10:
355-361, 2004
Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, Koide H: Effect of
troglitazone on urinary albumin excretion and serum type IV collagen concentrations in
type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 18: 308
-313, 2001
Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is
effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86: 280 -288, 2001
Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H: Comparative effects
of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin
excretion in diabetes patients. J Diabetes Complications 14: 250 -254, 2000
Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y,
Hori M: Effect of troglitazone on microalbuminuria in patients with incipient diabetic
nephropa-thy. Diabetes Care 21: 2135-2139, 1998
Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN: Addition of low-dose
rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic
patients. Diabet Med 17: 40 - 47, 2000
Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA: Expression and function of
peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 37:
722-727, 2001
Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K, Kondo M:
Troglitazone (CS-045) ameliorates albu-minuria in streptozotocin-induced diabetic
rats. Metabolism46: 981-983, 1997
Buckingham RE, Al-Barazanji KA, Toseland CDN, Slaughter M, Connor SC, West A, Bond
B, Turner NC, Clapham JC: Peroxisome proliferator-activated receptor- agonist, rosiglita-
zone, protects against nephropathy and pancreatic islet abnor-malities in Zucker fatty
rats. Diabetes 47: 1326 -1334, 1998
Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa
Thiazolidinedione compounds ameliorate glomerular dys-function independent of their
insulin-sensitizing action in dia-betic rats. Diabetes 49: 1022-1032, 2000
Baylis C, Atzpodien EA, Freshour G, Engels K: Peroxisome proliferator-activated receptor
[gamma] agonist provides supe-rior renal protection versus angiotensin-converting enzyme
inhi-bition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307: 854
- 860, 2003
Zhang Y, Park CW, Zheng F, Fan X, Striker G, Breyer MD, Guan Y: Endogenous PPAR
activity ameliorates diabetic ne-phropathy. J Am Soc Nephrol 14: 392A, 2003
McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH: Troglitazone halts
diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58: 2341-
2350, 2000
Zheng F, Fornoni A, Elliot SJ, Guan YF, Breyer MD, Striker LJ, Striker GE: Upregulation of
type I collagen by TGF- in mes-angial cells is blocked by PPAR activation. Am J Physiol
Renal Physiol 282: F639 -F648, 2002
Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M, Fujishima M: Peroxisome
proliferator-activated receptor 1 (PPAR 1) expresses in rat mesangial cells and PPAR
agonists modulate its differentiation. Biochim Biophys Acta 1497: 148 - 154, 2000
Ma L, Marcantoni C, Fogo AB: Peroxisome proliferator-acti-vated receptor- (PPAR ) agonist
troglitazone (TGL) protects against non-diabetic glomerulosclerosis. Lab Invest 80: 176A,
2000
Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM: Advanced glycosylation end
products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-
dependent pathway. Kidney Int 65: 1664 -1675, 2004
Onozaki A, Midorikawa S, Sanada H, Hayashi Y, Baba T, Katoh T, Watanabe T: Rapid change
of glucose concentration promotes mesangial cell proliferation via VEGF: Inhibitory
effects of thiazolidinedione. Biochem Biophys Res Commun 317: 24 -29, 2004
Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M: Peroxisome proliferator-
activated receptor- ligands inhibit TGF- 1-induced fibronectin expression in glomerular
mesangial cells. Diabetes 53: 200 -208, 2004
Chana RS, Lewington AJ, Brunskill NJ: efek Differential dari Peroksisom proliferator
activated receptor-gamma (PPAR gamma) ligan dalam sel tubulus proksimal:
Thiazolidinediones parsial agonis PPAR gamma. Ginjal Int 65: 2081-2090, 2004
Panchapakesan U, Pollock CA, Chen XM: Pengaruh glukosa yang tinggi dan agonis PPAR-
pada PPAR- ekspresi dan func-tion di HK-2 sel. Am J Physiol ginjal Physiol 287: F528 -
F534 2004